Since last year, a high-dose influenza vaccine has been available in Switzerland in addition to the standard vaccines, which is recommended and approved for people over 75 and for people aged 65 and over with an additional risk factor. Empirical data confirm the higher efficacy of quadrivalent high-dose compared to quadrivalent standard-dose influenza vaccines in these age groups.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Recognize CKD early and avoid dialysis
Screen diabetics and hypertensive patients regularly and use modern therapies
- From symptom to diagnosis
Abdominal pain – Inguinal testicles
- Case series
Mast cell activation syndrome (MCAS)
- Gestational diabetes
Significant CVD prevention through five lifestyle factors
- Modern therapeutic approaches for melanoma
Innovative strategies to overcome immunotherapy resistance
- Irritable Bowel Syndrome
“Best practice” recommendations for step-by-step clarification and stage-adapted therapy
- Nutritional supplements and cognition
5-HTP: The serotonin booster for cognition in old age
- Pulmonary hypertension